Last update 04 Aug 2025

Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
SL22P CART cells
Target
CD22 x PDL1
Action
inhibitors
Mechanism
CD22 inhibitors(CD22 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), Gene transference(Gene transference)
Therapeutic Areas
NeoplasmsRespiratory DiseasesUrogenital Diseases
Active Indication-
Inactive Indication
Non-Small Cell Lung CancerSarcomaUterine Cervical Cancer
Originator Organization
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
Active Organization-
Inactive Organization
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)
NCT04556669
/ Unknown statusPhase 1
Feasibility and Safety of Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
100 Clinical Results associated with Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)
Login to view more data
100 Translational Medicine associated with Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)
Login to view more data
100 Patents (Medical) associated with Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)
Login to view more data
100 Deals associated with Autologous aPD-L1 armored anti-CD22 CAR-T cells (Hebei Senlang Biotechnology)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 1
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
01 Aug 2020
SarcomaPhase 1
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
01 Aug 2020
Uterine Cervical CancerPhase 1
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
01 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free